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Oarvedilol for Anthracycline
ardiomyopathy Prevention
alay et al. (1), in a population of apparently unselected patients
eceiving their first 6 cycles of anthracyclines, found in their
ontrol group a high incidence of functional cardiomyopathy: 24%
f their patients had at the final examination an ejection fraction of
0% or less. This incidence of cardiac dysfunction is higher than
he expected one for patients beginning their exposure to anthra-
yclines (2); this must be clearly explained, because it is the base of
he suggested treatment effect: only one patient of the carvedilol
roup developed functional cardiomyopathy. The only risk factor
or cardiomyopathy development that is apparently present in this
elatively young population is a high accumulated dose, with a
ean of 513.6 mg/m2 for adriamycin users and of 770.4 mg/m2 for
pirubicin users, in the control group. The carvedilol-treated group
eceived about the same mean doses.
Unfortunately, the investigators do not report the standard
eviation of the total doses administered. If there is a large
ispersion of data, the “nonsignificant” Student t test reported for
he comparison of total doses between groups loses confidence.
arge dispersion of data in this regard may imply different
istribution of total doses, with consequent different risks to both
roups, independently of the influence of treatment on cardiac
rognosis. When one is trying to reach conclusions with a small set
f data, meticulous presentation of both data and appropriate
tatistics is mandatory.
Also, the total dose of adriamycin and epirubicin appears
nusually high in a population naïve to previous anthracycline
xposure: we calculate cycles of about 87 mg/m2 for adriamycin
sers and about 130 mg/m2 for epirubicin users, which are not the
sual doses for breast cancer or lymphoma treatment. This also
equires clarification.
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e thank Drs. Florenzano and Salman for their valuable com-
ents regarding our study (1). Four types of anthracycline cardio-
oxicity are described: acute, subacute, chronic, and late onset.
cute complications can be seen in 0.4% to 41% of patients (2).
e performed echocardiography after chemotherapy and evalu-
ted both acute and subacute cardiotoxicity. Dilated cardiomyop-
thy is the most important complication of chemotherapy. It is
ssociated with certain risk factors: dose, administration rate,
ender, age, underlying heart diseases, hypertension, irradiation,
nd the human epidermal growth factor receptor-2.
Mean decrease in left ventricular ejection fraction (LVEF) in
ur control group was 16.6%. It was demonstrated that gradual
ecrease in LVEF was 1.9% with every 50-mg anthracycline dose.
ecrease in LVEF in our study was concordant with this infor-
ation. However, both LVEF and cardiomyopathy incidence may
hange with risk factors. The incidence of subclinical cardiomy-
pathy is not exactly known. It has been demonstrated that
oxorubicin-induced subclinical cardiomyopathy can be 27.6% (3),
nd the troponin I increase can be 33% of patients after chemo-
herapy, and this increase is associated with decreased LVEF (4).
n another study (5), patients who had received chemotherapy
ere randomized either to receive or not to receive an angiotensin-
onverting enzyme inhibitor, and the primary end point was10%
ecrease in LVEF. The primary end point was 0% in the treatment
roup and 43% in control subjects. These results suggest that
ystolic dysfunction may occur in many patients. Decompensated
eart failure was shown in one patient in our groups, but
ubclinical cardiomyopathy was demonstrated in additional pa-
ients.
The main result of our study showed that carvedilol may prevent
nthracycline-induced cardiomyopathy. Our study is a preliminary
ne in this issue. We enrolled cancer patients, so patients with
ifferent types of disease at different stages were included in the
rial. Although we had a small number of patients, the distribution
f disease types and the anthracycline dose used in the patient
roup were well balanced between the groups. The dose of
nthracycline changes with the treatment scheme. Moreover, the
umber of standard cycles is 6; in some cases additional cycles may
e used depending on the scheme employed and the oncologist’s
reference. Most of our patients received adriamycin, and the
egular dose was 65 to 75 mg/m2, but higher doses were used in
ome patients. Furthermore, it is known that the cardiotoxicity
ncidence increases with increased doses of adriamycin and epiru-
icin above 550 and 900 mg/m2, respectively (6).
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